



OTCQB: **BCTXF**
TSX-V: **BCT**

BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off-the-shelf personalized approach to immunotherapy. The company recently achieved **positive proof-of-concept in a Phase I/IIa clinical trial** for its lead product candidate, **Bria-IMT™**, in patients with advanced breast cancer (ClinicalTrials.gov as NCT03066947). The trial was being conducted along with the co-development of **BriaDX™**, the company's companion diagnostic test. Currently, BriaCell is conducting an FDA approved combination study of **Bria-IMT™** with pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), for patients with advanced breast cancer (ClinicalTrials.gov as NCT03328026). Capitalizing on insights gained with **Bria-IMT™**, BriaCell is developing **Bria-OTS™**, the first **"off the shelf" personalized immunotherapy** for the treatment for advanced stage Breast Cancer. Finally, BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.

Investment Highlights

- Developing **Bria-OTS™**, the **First Off-the-Shelf Personalized Immunotherapy**
- Targeting Adv. Breast Cancer: Unmet medical need (over 40,000 deaths in the US in 2017)
 - **\$1 Bil- \$5 Bil** market opportunity depending on patient treatment stage
- Impressive results in 2 proof-of-concept clinical trials
 - Rapid Response Rate; Repeated Response following re-treatment; Excellent Safety Profile
- Completed enrollment in Phase I/IIa clinical trial of **Bria-IMT™** with outstanding safety & efficacy data
 - **Initiated Phase IIa Combination Study of Bria-IMT™ with Keytruda® (Merck & Co., Inc.)**
- Developing **Bria-OTS™** along with **BriaDX™**, its companion diagnostic test
 - Ability to match and treat ~90% of patient population with Off-the-Shelf personalized immunotherapy
- Experienced Management has been involved in over 10 drug approvals
- Significant Near-Term News-flow

BriaCell Leadership Team

William V. Williams, MD
President, Chief Executive Officer

Gadi Levin, CA, MBA
Chief Financial Officer

Markus Lacher, PhD
Senior Director, R&D

Farrah Dean, MSc, MBA
Manager, Corp. Development

Board of Directors

Saeid Babaei, PhD, MBA, Chairman
President & CEO, AbCelex
Technologies

Rahoul Sharan, CA, Director
President, KJN Management Ltd.

Martin Schmiege, CPA, Director
General Manager, Soar Ventures

Charles Wiseman, MD, Director &
Co-Founder; Clinical Professor of
Medicine, Division of Medical
Oncology, Keck-USC School of
Medicine

William V. Williams, MD, Director
President & CEO, BriaCell